Melanoma

Skin Cancer Detection Gets AI-Powered Dermatopathology Tools

Gestalt and Primaa have partnered to integrate AI-powered dermatopathology tools in the PathFlow platform, enhancing skin cancer diagnostics.

Melanoma

Castle Biosciences’ Melanoma Test Influences Patient Care Decisions

Respondents who used DecisionDx-Melanoma stated that a high-risk test result in a thin melanoma tumor would impact patient treatment plans.

Melanoma

Clinical Studies Evaluate DermaSensor’s Skin Cancer Detection Device

DermaSensor presented a pooled analysis from clinical studies evaluating the performance of the company's device in detecting skin cancer.

New Biomarkers Can Predict Response to Melanoma Immunotherapy Treatment

Feb 18, 2022 | Melanoma

Researchers have discovered blood biomarkers that can help identify if someone suffering from Melanoma can benefit from immune checkpoint inhibitors.

Foundation Medicine Receives FDA Approval for its Tissue-Based Genomic Profiling Test

Dec 28, 2021 | Melanoma, Tissue Processing

FoundationOne CDx is used as a companion diagnostic for two groups of FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies.

Virtual Histology Eliminates Need for Invasive Skin Biopsies

Nov 19, 2021 | Histology, Melanoma, Microscopy

Researchers used deep learning framework to transform microscopy images of intact skin into histochemically stained sections imaged on microscope slides.

AI Breakthrough Announced in Melanoma Detection

Oct 7, 2021 | Melanoma

Proscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.

Castle Biosciences to Acquire Myriad MyPath Laboratory

May 21, 2021 | Company News, Melanoma

Castle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.

Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer

May 4, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types

The blood test followed by PET-CT imaging was 99.6% specific for cancer.

Biocare Medical Launches Seven Antibody Markers for Clinical Diagnostic and Cancer Research Applications

Apr 27, 2020 | Biochemicals & Chemical Reagents, Cancer, Melanoma, Tissue Processing

The launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.

Bio-Rad Introduces Anti-Ipilimumab Antibodies

Apr 27, 2020 | Biochemicals & Chemical Reagents, Cancer, Melanoma

The highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor ipilimumab.

Interventional Study to Evaluate Multicancer Early Detection Test

Apr 21, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types

The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.

Study Offers Promise for Multicancer Detection from a Single Blood Draw

Apr 6, 2020 | Breast, Cancer, Cervical (HPV), Leukemia, Lung Cancer, Lymphoma, Melanoma, Molecular Diagnostics, Pancreatic, Prostate, Unknown Origin & Other Cancer Types

Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.

Improved pH Probes May Aid in Monitoring Cancer

Feb 7, 2020 | Cancer, Melanoma

Nanopipettes with zwitterionic membranes may offer improved monitoring of changes in pH surrounding living cells, which can indicate traits of invasive cancer cells and their response to treatment.